China Life to Inject Additional RMB5 Billion Into Connected Real Estate Partnership

China Life Insurance Co ( (HK:2628) ) has shared an update.

China Life Insurance Company Limited plans to further increase its capital contribution to an existing real estate investment partnership with China Life Properties, its connected-party general partner, by RMB5 billion by 31 December 2025. The injection, funded from internal resources, will lift the partnership’s total committed capital to RMB18.901 billion, nearly all of which will come from China Life Insurance, and is classified as a connected transaction subject only to reporting and announcement requirements under Hong Kong listing rules. The partnership focuses on equity investments in core real estate projects in first-tier and strong second-tier Chinese cities and has already taken a 49.895% stake in the company developing Project INDIGO II, a large flagship commercial complex in Beijing slated to open between 2026 and 2028; the additional funds are intended to support the ongoing construction and development of this asset, reinforcing China Life’s strategy of using high-quality, income-generating property to back its long-term insurance liabilities.

The most recent analyst rating on (HK:2628) stock is a Buy with a HK$32.00 price target. To see the full list of analyst forecasts on China Life Insurance Co stock, see the HK:2628 Stock Forecast page.

More about China Life Insurance Co

China Life Insurance Company Limited is a major life insurer in mainland China, offering a broad range of life insurance and related financial products. The company invests its substantial insurance funds across various asset classes, including real estate, to align long-duration liabilities with stable, low-risk returns in key urban markets across the country.

Average Trading Volume: 65,537,768

Technical Sentiment Signal: Buy

Current Market Cap: HK$1243.2B

Find detailed analytics on 2628 stock on TipRanks’ Stock Analysis page.